复发性、同时性及异时性食管鳞状细胞癌重复内镜黏膜下剥离术的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析检索PubMed、Google Scholar和Cochrane(建库至2024年11月),纳入5项研究、232例患者、258处病灶,评估重复内镜黏膜下剥离术(ESD)治疗位于或邻近既往ESD瘢痕的复发性食管鳞状细胞癌(ESCC)的疗效与安全性。汇总整块切除率为90.07%,完全切除率为79.59%,穿孔率5.21%,狭窄率10.26%,迟发性出血率4.05%,重复ESD后复发率8.60%。作者认为重复ESD用于复发性ESCC显示出可接受的临床结局,但存在技术挑战和不良事件变异性,尚需进一步研究以优化结局。
要点
- 重复ESD治疗复发性ESCC的汇总整块切除率为90.07%(95%CI 82.46-95.70;I²=67.77%)。
- 汇总完全切除率为79.59%(95%CI 67.71-89.31;I²=66.93%)。
- 穿孔率5.21%、狭窄率10.26%、迟发性出血率4.05%、复发率8.60%。
核心结论
- 重复ESD用于复发性ESCC显示出可接受的临床结局,尽管存在技术挑战和不良事件变异性,似为可行的内镜选择,并强调需进一步研究以优化结局。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Google Scholar和Cochrane(建库至2024年11月),纳入5项关于重复ESD治疗既往ESD瘢痕处或邻近复发性ESCC的研究。
- 共纳入232例患者(平均年龄69.4岁;男性85.35%)和258处病灶。
- 主要结局为整块切除和完全切除,次要结局为不良事件(穿孔、狭窄、出血)和复发;采用随机效应模型进行Meta分析,以I²统计量评估异质性。
主要发现
- 汇总整块切除率为90.07%(95%CI 82.46-95.70;I²=67.77%)。
- 汇总完全切除率为79.59%(95%CI 67.71-89.31;I²=66.93%)。
- 不良事件率包括穿孔5.21%、狭窄10.26%、迟发性出血4.05%。
- 重复ESD后复发率为8.60%(95%CI 3.08-16.53;I²=72.66%)。
关键数值与推荐
- 整块切除率90.07%(95%CI 82.46-95.70;I²=67.77%)。
- 完全切除率79.59%(95%CI 67.71-89.31;I²=66.93%)。
- 穿孔率5.21%,狭窄率10.26%,迟发性出血率4.05%。
- 重复ESD后复发率8.60%(95%CI 3.08-16.53;I²=72.66%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 整块切除率存在异质性,I²=67.77%。
- 完全切除率存在异质性,I²=66.93%。
- 复发率存在异质性,I²=72.66%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Endoscopic submucosal dissection (ESD) is the preferred treatment for early-stage esophageal squamous cell carcinoma (ESCC), providing a minimally invasive endoscopic alternative to surgery with potential for complete resection and organ preservation. This study aims to evaluate the efficacy and safety of repeat ESD for recurrent ESCC lesions located on or near previous ESD scars. METHODS: A systematic search of PubMed, Google Scholar, and Cochrane (from inception to November 2024) identified studies on repeat ESD for recurrent ESCC near previous ESD scars. Primary outcomes were en bloc resection and complete resection. Secondary outcomes included adverse events (perforation, stricture, bleeding) and recurrence. Meta-analysis was conducted using a random-effects model, and heterogeneity was assessed with I2 statistics. RESULTS: Five studies with 232 patients (mean age 69.4 years; 85.35% male) and 258 lesions were analyzed. The pooled en bloc resection rate was 90.07% (95% CI, 82.46-95.70; I2 = 67.77%), and the complete resection rate was 79.59% (95% CI, 67.71-89.31; I2 = 66.93%). Adverse event rates included perforation at 5.21%, stricture at 10.26%, and delayed bleeding rate of 4.05%. Recurrence after repeat ESD was 8.60% (95% CI, 3.08-16.53; I2 = 72.66%). CONCLUSIONS: Repeat ESD demonstrated acceptable clinical outcomes for recurrent ESCC. Despite technical challenges and variability in adverse events, it seems to be a viable endoscopic option, emphasizing the need for further research to optimize outcomes.
引用
- Kalsi H, Rai A, Arora SS, et al. Efficacy and safety of repeat endoscopic submucosal dissection for recurrent, synchronous, and metachronous esophageal squamous cell carcinoma: a systematic review and meta-analysis. Gastrointest Endosc. 2025. PMID: 40513802. doi:10.1016/j.gie.2025.05.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。